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Background: Neuromyelitis optica (NMO) is a rare relapsing auto-immune disease of the central nervous system
which is sometimes found in association with other autoimmune disorders including Sjogren’s syndrome. We
present the case of a middle aged female with Sjogren’s syndrome (SS) and Neuromyelitis optica spectrum disorders
(NMOSD) who had a rapidly declining neurological illness that responded to immunosuppressive therapy.
Case presentation: A 51-year-old female with Sjogren’s syndrome and recent history of varicella zoster infection
presented with right upper and lower extremity weakness of one week duration. She was noted to have contrast
enhancement at C2-C4 cord levels on cervico-thoracic MRI. Comprehensive work up was negative except for presence
of a mild lymphocytic pleocytosis and oligoclonal bands in the CSF. She was diagnosed with transverse myelitis secondary
to varicella zoster infection and was treated with high dose steroids in addition to acyclovir with improvement in her
symptoms. Two months later she developed left upper and lower extremity weakness, bilateral dysesthesias and urinary
incontinence. Repeat MRI of the cervico-thoracic spine revealed worsening enhancement at lower cervical cord levels
(C5-7) with extension to T1. CSF analysis was unchanged; however immunological work up was abnormal for elevated
NMO-IgG/AQP4 antibody. She was diagnosed with NMOSD and was treated with immunosuppressive therapy. Initially
with IV methylprednisone and Cyclophosphamide therapy followed by Mycophenolate mofetil (MMF) maintenance
therapy with good response. Repeat MRI 6 months later showed near complete resolution of previous abnormal cord
signal changes.
Conclusion: One needs to recognize the relationship between autoimmune diseases especially SS and NMOSD. The
presence of NMO antibody has been associated with a relapsing disease course and a careful follow-up, besides use of
remission maintenance agents such as MMF and Azathioprine are important to consider.
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Sjögren’s syndrome (SS) is a chronic systemic disease
characterized by inflammation and dysfunction of exo-
crine glands. Up to 65% of primary SS patients can ex-
perience extra glandular features including pulmonary,
gastrointestinal, hematologic and neurologic disorders
[1]. Neurologic disorders are severe extraglandular fea-
tures of SS. Longitudinally extensive myelitis has been* Correspondence: enaren10@gmail.com
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article, unless otherwise stated.reported in SS [2,3]. Neuromyelitis optica (NMO) also
known as Devic syndrome is a rare relapsing auto-
immune disease of the central nervous system (CNS)
which is sometimes found in association with other
autoimmune disorders, including SS. Based on the re-
vised criteria by Wingerchuck et al, a diagnosis of NMO
can be made in the presence of both absolute and two
of three supportive criteria [4]. The absolute criteria
include optic neuritis and myelitis; while the supportive
criteria are magnetic resonance imaging (MRI) evidence
of a contiguous spinal cord lesion (3 or more segments
in length), MRI brain non-diagnostic for multiple sclerosis
and serological evidence of NMO-IgG or aquaporin 4
(AQP4) antibodies. NMO spectrum disorders (NMOSD)entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 MRI T2 weighted sequence of the cervical region
showing contrast enhancing lesion from C2-C4.







Total nucleated cells 11 16 0-5
RBC 1245 38 0
Neutrophils 15 01 0-6
Lymphocytes 74 82 40-80
Protein 60 44 15-45
Gross appearance Colorless Colorless Colorless
Oligoclonal bands Present Present
IgG Index 15.8 10.6 0-6.6
IgG/Albumin ratio 0.43 0.47 0-0.27
Culture (aerobic, fungal, viral) Negative Negative Negative
Cytology Negative Negative Negative
PCR (Varicella, Lyme) Negative Negative Negative
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express NMO antibody and share features with NMO but
do not meet the strict diagnostic criteria specified previ-
ously [5].
Herein we present the case of a middle aged female
with SS and NMOSD who had a rapidly declining
neurological illness that responded to immunosuppres-
sive therapy. Prompt recognition and treatment can alter
the course of this uncommon yet devastating illness,
though the prognosis and response to therapy is not
always favorable.
Case presentation
A 51 year old right hand dominant Caucasian female with
history of hypothyroidism (microsomal and thyroid anti-
body positive), celiac disease and SS (seropositive for SSA,
ANA, hypergammaglobulinemia, intermittent parotid swell-
ing with mild oral/ocular sicca) experienced right C5 der-
matomal varicella zoster infection seven weeks previously
and then presented with right upper and right lower ex-
tremity weakness of one week duration. The symptoms got
progressively worse to the point that she had difficulty with
ambulation. She had associated burning dysesthesias of left
thigh. The patient’s neurological examination was remark-
able for hypertonia, decreased power (3/5), hyperreflexia
along with sensory loss in the right upper and lower ex-
tremity and hyperesthesia in the entire left lower extremity.
Gadolinium contrast enhanced magnetic resonance
imaging (MRI) of the head was normal but MRI of the
cervico-thoracic spine revealed an enhancing intrame-
dullary lesion from C2 to C4, centrally into the right of
the midline with signal changes at the T1 level without en-
hancement or expansive appearance (Figure 1). Cerebro-
spinal fluid (CSF) analysis was abnormal for a mild
lymphocytic pleocytosis, marked elevation of IgG and
prominent oligoclonal bands (Table 1). Comprehensive
infectious workup including blood cultures for bacteria,
polymerase chain reaction for varicella zoster, herpes sim-
plex virus, and serologies for Lyme disease and syphilis
were negative. Differentials for non-infectious inflamma-
tory myelitis were considered; including paraneoplastic
myelitis and myelitis with Sjogren’s syndrome. NMO
antibodies were not obtained during this presentation.
The patient was treated with 1 gram of intravenous (IV)
methylprednisone and 800 mg of oral acyclovir for 5 days
for presumptive diagnosis of transverse myelitis secondary
to varicella zoster infection with improvement in her
symptoms. She was discharged on oral prednisone with
instructions to taper and discontinue the drug over the
next 1 week.
Two months later, she developed left upper and lower
extremity weakness, bilateral lower extremity dysesthe-
sias and urinary incontinence. Examination confirmed 4/
5 left hemiparesis with brisk reflexes, bilateral ankleclonus along with pinprick loss in both lower extremities.
Repeat MRI of the spine revealed worsening enhancement
at lower cervical cord region (C5-7) with extension to T1
level (Figure 2). Repeat CSF analysis showed a lymphocytic
pleocytosis, increased IgG synthesis index and positive
oligoclonal bands (Table 1). Immunological work up was
abnormal for NMO-IgG/AQP4 antibody (Table 2). An
ophthalmologic evaluation was negative for optic neuritis.
The patient’s relapsing neurological illness was felt to
represent NMOSD from underlying long standing SS.
She was treated with 1 gram of IV methylprednisone and
started on 1 gram of IV cyclophosphamide (CTX) therapy
for worsening motor-sensory deficit. She was discharged
Figure 2 MRI T2 weighted sequence of the cervical MRI
showing abnormal signal changes extending from C2-T1 with
worsening enhancement at lower cervical cord levels.
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CTX infusions.
After her second monthly CTX infusion, patient had a
relapse with right upper and lower extremity weakness,
dysesthesias in the parieto-occipital scalp region and right
leg along with urinary incontinence. The patient was
placed on 5 days of pulse IV steroids with improvement in
her symptoms. She was discharged on 60 mg of daily pred-
nisone which was slowly tapered over 6 months. She con-
tinued to show clinical improvement despite persistence of
NMO-IgG antibodies. After 5 infusions of monthly CTX
therapy, maintenance treatment with Mycophenolate
Mofetil (MMF) was started. She has remained on MMF
without recurrence of symptoms for over 18 months. SheTable 2 Summary of the immunological work up
Immunology Patient Normal
ANA >1:640 (speckled pattern) <1:40
Anti-ds DNA <1:10 <1:10
SS-A/Ro antibodies >8.0 0.0-0.9
SS-B/Lo antibodies <0.2 0.0-0.9
Scl-70 antibodies <0.2 0.0-0.9
Jo 1 antibodies 0.2 0.0-0.9
NMO-IgG (AQP4 antibody) >160 <1.6
Anti CCP antibodies 4.0 0.0-19.9
dRVVT 34.5 32.4-43.5
PTT-LA 39 42-64
Anticardiolipin screen Negative Negative
Beta 2 Glycoprotein 1 screen Negative Negativehas no residual motor or sensory deficits. Repeat MRI of
the cervico-thoracic spine 6 months after her last CTX
infusion, prednisone and MMF showed near complete
resolution of previous abnormal cord signal changes
(Figure 3).
Discussion
A wide spectrum of neurologic manifestations may
accompany primary SS. These can include asymptomatic
brain lesions on MRI [6] to symptomatic brain lesions,
meningitis, myelopathy, cranial neuropathy, sensorimotor
polyneuropathy and mononeuritis multiplex. Spinal cord
involvement in primary SS may resemble primary progres-
sive multiple sclerosis, progressive myelopathy or trans-
verse myelitis. The pathogenesis of CNS involvement in
primary SS is unclear. A vasculitic process and auto-
immune demyelination have been proposed to be possible
mechanisms for this process [7,8]. Unlike systemic lupus
erythematosus (SLE), patients with primary SS do not
demonstrate anti-neuronal or anti-ribosomal antibodies to
suggest additional immune-pathologic mechanism other
than humoral immune response [9]. Primary SS can mimic
as well as coexist with multiple sclerosis [10] though only a
very small percentage of multiple sclerosis patients have
detectable SS [11]. Nonetheless it can pose a significant
diagnostic and therapeutic challenge in clinical practice.
The differential diagnosis for neurologic manifestations
of SS is broad including infections, neoplasms and meta-
bolic disorders; work-up in an individual patient must be
thorough to exclude them. Tests for anti-phospholipidFigure 3 MRI T2 weighted sequence of the cervical MRI after
Prednisone, Cyclophosphamide and Mycophenolate therapy,
demonstrates improvement and near resolution of previously
noted signal abnormalities.
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photon emission computed tomography scans must be
considered when entertaining a diagnosis of neurologic
SS. Brain biopsy is done only in rare instances when the
work up is unrevealing and precise etiology is unclear.
NMOSD is a relapsing neurological illness that has
been sometimes reported in association with primary SS
and SLE. NMO is characterized by recurrent episodes of
myelitis and optic neuritis and most patients have a
unique antibody against NMO IgG/ AQP4. Patients who
have NMO IgG/AQP4 antibodies have frequent relapses
compared to those who do not have the antibodies [12].
NMOSD is manifested by loss of AQP4, which is a
bidirectional water channel found in the cell membrane
of foot processes of the astrocytes and on the ependymal
cells in the CNS [13]. The presence of NMO IgG anti-
bodies against these AQP4 channels aids in the diagnosis
of NMO in patients with neurologic manifestations
[14,15]. Following the discovery of NMO IgG antibodies,
Weinshenker et al reported the specificity of NMO IgG
antibodies to be 91% and the sensitivity to be 75%, in
distinguishing between MS and NMO [16]. Various
HLA alleles such as HLA-DRB1*03, HLA-DPB1*0501
and structural changes in the AQP4 channel have been
affiliated with an increased susceptibility to developing
NMO [17]. Studies have shown that an inflammatory
process such as an infection (viral or bacterial) can be a
trigger in developing immunogenicity [18]. It may also
play a role in damaging the blood brain barrier allowing
NMO IgG penetration [19]. NMO IgG antibodies cause
destruction of the AQP4 channels on the astrocyte foot
processes by complement mediated cytotoxicity via the
lytic complex C5b9 [20]. Antibody production by B-cells
and T-helper cell activation of cytokines such as IL-16
and IL-17 are thought to play a crucial role in the subse-
quent destruction of the AQP4 channels [21,22]. The
consequential loss of oligodendrocytes results in demye-
lination leading to the neurological signs seen in NMO
[23]. The lesions in NMO are characterized by extensive
infiltration, acute axonal loss and fibrosis [24].
There is not enough evidence yet to consolidate the
etiologic relationship between infectious or parainfec-
tious NMO syndromes; this relationship currently only
exists based on a temporal spectrum [25]. A review of
parainfectious NMO syndromes by Sellner et al demon-
strated 6 out of 11 patients with prior VZV infection
(with vesicular eruptions) who presented with features
of transverse myelitis and visual problems [25]. A propor-
tion of the patients fit the criteria for NMO spectrum;
however most cases were not associated with recurrent
attacks and all but one were seronegative for AQ4 an-
tibodies [25]. A case report by Heerlein et al demon-
strates a similar patient as ours who presented with
features of LETM within two weeks following herpeszoster rash. The patient was seropositive for AQP4
antibodies, with subsequent remission of symptoms and
disappearance of AQP4 antibodies following plasma-
pheresis [26].
Relapsing NMO carries a poor prognosis, thereby validat-
ing the need for early testing and treatment. It has been re-
ported to have a 5 year survival rate of approximately 80%
[27]. The cumulative effect of recurrent attacks renders a
debilitating outcome, including permanent disabilities
requiring assistive devices for ambulation and monocular
blindness [27]. A proportion of deaths occurring within the
first 5 years are due to respiratory failure [27].
NMO and NMOSD are rare diseases with no consen-
sus on treatment guidelines. The treatment options are
empiric and based on disease severity ranging from
plasmapheresis, corticosteroids, CTX and rituximab to
oral agents such as azathioprine, MMF and methotrex-
ate. Early initiation of systemic steroids alone or in
combination with other immunosuppressive therapies is
most often used. In our patient with relapsing disease
course, combination of steroids and CTX was successful
in achieving disease stabilization, resolution of cord
enhancing lesions and recovery from a declining clinical
course. MMF has helped maintain disease remission
despite persistent NMO antibody detectable in the
serum.
The rationale for therapy with MMF can be explained
by the predominant role of humoral immunity in NMO.
A subgroup analysis in a small retrospective trial in
patients receiving a median dose of 2 gm/day of MMF
demonstrated a decrease in the median annual relapse
rate from 1.3 (range 0.23-11.8) in the pretreatment
group to 0.09 (range 0-1.5) in the post treatment group
at a median follow up of 28 months [28]. A single case
report published in 2006 reported a 9 y/o girl treated
with MMF successfully with no relapse at 2 years follow-
ing development of vertebral fractures with steroids and
continued relapses on Azathioprine [29]. Rituximab has
similarly shown to reduce the levels of NMO IgG/
AQP4 [30,31] and thereby clinical improvement.
Conclusion
The spectrum of neurologic disorders in Sjögren’s syn-
drome remains broad and diagnosis is frequently delayed.
Conventional treatment strategies using corticosteroids
are effective for acute flare ups of severe manifestations
such as NMO, NMOSD and transverse myelitis. Treat-
ment with cytotoxic agents and rituximab are useful in
achieving disease remission, although treatment intensity
should be guided by severity of clinical presentation. The
presence of NMO antibody has been associated with a
relapsing disease course and a careful follow-up, besides
use of remission maintenance agents such as MMF and
Azathioprine are important to consider. There remain
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tenance medications and utility of following NMO titers
in predicting future risks of flare. Further studies with long
term patient follow-ups will answer these potentially
important clinical questions.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
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